Elite Pharmaceuticals, Inc. (ELTP)
| Previous Close | 0.1292 |
| Open | 0.1295 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1250 - 0.1330 |
| 52 Week Range | 0.0300 - 0.2100 |
| Volume | |
| Avg. Volume | 944,012 |
| Market Cap | 132.118M |
| Beta (5Y Monthly) | -0.14 |
| PE Ratio (TTM) | 6.49 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
Conference Call Scheduled for Thursday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pharmaceutical company engaged in the development, ...
- ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
Financials for Third Quarter Fiscal Year 2024 Ended December 31, 2023 will be released on February 14, 2024 NORTHVALE, NJ / ACCESSWIRE / February 8, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical ...
- ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
NORTHVALE, NJ / ACCESSWIRE / December 26, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced ...
